Pharmaxis Ltd will be commencing its Phase 3 clinical trials for Bronchitol, testing its safety and effectivity against bronchiectasis, a lung disease characterized by abnormal destruction and dilation of the large airways.
“This pivotal trial for Bronchitol is the final step before registration in Australia, New Zealand and the European Union.
When complete, the results of the study should provide sufficient data for a marketing application to be lodged.”
Bronchitol is a is medication being developed not only for the treatment of chronic obstructive pulmonary disease such as bronchoectasis and chronic bronchitis, but also against cystic fibrosis. The drug is produced from mannitol, a naturally occuring sugar, and comes as inhalable dry powder that can be administered via a hand-held, pocket-sized device.